Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030
The Anticonvulsants Market size was estimated at USD 12.03 billion in 2023 and expected to reach USD 13.07 billion in 2024, at a CAGR 8.71% to reach USD 21.59 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Anticonvulsants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticonvulsants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.
Market Segmentation & Coverage
This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug types
AMPA
Anxiety
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Anticonvulsants Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticonvulsants Market?
- What are the technology trends and regulatory frameworks in the Anticonvulsants Market?
- What is the market share of the leading vendors in the Anticonvulsants Market?
- Which modes and strategic moves are suitable for entering the Anticonvulsants Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Anticonvulsants Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of epilepsy among young and senior population
- 5.1.1.2. Rising government initiatives supporting epilepsy awareness
- 5.1.1.3. Expanding use in treating nonepileptic conditions
- 5.1.2. Restraints
- 5.1.2.1. Availability of substitutes options for pain management
- 5.1.3. Opportunities
- 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
- 5.1.3.2. Emergence of new-generation antiepileptic drugs
- 5.1.4. Challenges
- 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Anticonvulsants Market, by Drug types
- 6.1. Introduction
- 6.2. AMPA
- 6.3. Barbiturate
- 6.4. Benzodiazepine
- 6.5. Carbamate Anticonvulsants
- 6.6. Carbonic Anhydrase Inhibitor
- 6.7. Dibenzazepine
- 6.8. Triazine
- 7. Anticonvulsants Market, by Indication
- 7.1. Introduction
- 7.2. Anxiety
- 7.3. Bipolar Disorder
- 7.4. Borderline Personality Disorder
- 7.5. Epilepsy
- 7.6. Fibromyalgia
- 7.7. Migraine
- 7.8. Neuropathic Pain
- 8. Americas Anticonvulsants Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Anticonvulsants Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Anticonvulsants Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Abbott Laboratories
- 12.1.2. Astrazeneca PLC
- 12.1.3. Bausch Health Companies Inc.
- 12.1.4. Biocon Limited
- 12.1.5. Cadila Pharmaceuticals Limited
- 12.1.6. Cipla, Inc.
- 12.1.7. Dr. Reddy's Laboratories Limited
- 12.1.8. Eisai Co., Ltd.
- 12.1.9. GlaxoSmithKline PLC
- 12.1.10. Glenmark Pharmaceuticals Ltd.
- 12.1.11. Jazz Pharmaceuticals, Inc.
- 12.1.12. Johnson & Johnson Services, Inc.
- 12.1.13. Lifecare Neuro Products Limited
- 12.1.14. Lundbeck A/S
- 12.1.15. Mankind Pharma Ltd.
- 12.1.16. Merck KGaA
- 12.1.17. Novartis AG
- 12.1.18. Novo Nordisk A/S
- 12.1.19. Otsuka Pharmaceutical Co., Ltd.
- 12.1.20. Pfizer Inc.
- 12.1.21. Sanofi S.A.
- 12.1.22. Sunovion Pharmaceuticals Inc.
- 12.1.23. Takeda Pharmaceutical Company Limited
- 12.1.24. Teva Pharmaceutical Industries Ltd.
- 12.1.25. Wockhardt Limited
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
- FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTICONVULSANTS MARKET DYNAMICS
- FIGURE 7. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
- FIGURE 8. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook